RVL Pharmaceuticals PLC
OTC:RVLPQ
RVL Pharmaceuticals PLC
OTC:RVLPQ
Price:
0
USD
Market Closed
Market Cap:
$0
Relative Value
There is not enough data to reliably calculate the relative value of RVLPQ.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RVLPQ
Relative Value
Base Case
Not Available
Multiples Across Competitors
RVLPQ Competitors Multiples
RVL Pharmaceuticals PLC Competitors
RVL Pharmaceuticals PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
RVL Pharmaceuticals PLC
OTC:RVLPQ
|
111 USD | 0 | -0 | 0.5 | 0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
961.6B USD | 14.8 | 46.6 | 31.4 | 33.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.7B USD | 6.2 | 22 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
295B CHF | 4.8 | 31.4 | 13.2 | 15.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
242.6B GBP | 5.6 | 32.3 | 17.8 | 25.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.1B CHF | 5.7 | 22.8 | 14 | 18 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.6B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.4 | 9.8 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.7B USD | 2.5 | 20 | 7.5 | 10 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
92.5B GBP | 2.8 | 16.2 | 8.1 | 11.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
